What are the best treatments for Non-Hodgkin's lymphoma?

Treatments for Non-Hodgkin's lymphoma are highly personalized based on the specific subtype, stage, and genetic profile of the cancer. Current standards typically involve combinations of immunotherapy, chemotherapy, and targeted therapies, often tailored to the patient’s overall health and the aggressiveness of the lymphoma.

What are the primary treatments for Non-Hodgkin's lymphoma?

First-line treatment for Non-Hodgkin's lymphoma depends on whether the disease is indolent (slow-growing) or aggressive (fast-growing). Common therapeutic approaches include:

• Immunotherapy: Medications like rituximab (Rituxan) or obinutuzumab (Gazyva) are frequently used to target specific proteins on lymphoma cells.


• Chemotherapy: Regimens such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) remain a cornerstone for many aggressive forms of Non-Hodgkin's lymphoma.


• Targeted Therapy: Small molecule inhibitors or monoclonal antibodies designed to disrupt specific signaling pathways within cancer cells.


• Radiation Therapy: Often used for localized disease or for palliative symptom management.

What is the role of emerging therapies and clinical trials?

For patients with relapsed or refractory Non-Hodgkin's lymphoma, CAR T-cell therapy (such as axicabtagene ciloleucel) has emerged as a transformative treatment. Clinical trials continue to explore bispecific antibodies and novel combination therapies to improve long-term outcomes for those whose Non-Hodgkin's lymphoma does not respond to conventional protocols.

Which specialists should be on the care team?

Managing Non-Hodgkin's lymphoma requires a multidisciplinary approach. Your care team should ideally include a hematologist-oncologist, a radiation oncologist, and a specialized oncology nurse. Depending on individual needs, physical therapists and nutritionists play a vital role in maintaining quality of life throughout the treatment process.

How does treatment effectiveness vary between patients?

Treatment success for Non-Hodgkin's lymphoma varies significantly based on biomarkers, age, and comorbidities. Because Non-Hodgkin's lymphoma comprises over 60 distinct subtypes, what works for one patient may not be effective for another, necessitating precise molecular diagnostic testing.

Next steps

• Consult with a board-certified hematologist-oncologist to discuss your specific subtype.


• Join the 96 members in our DiseaseMaps.org community to share experiences and find support.


• Ask your physician about clinical trial eligibility via ClinicalTrials.gov.


• Maintain a detailed symptom and treatment journal to discuss at your next appointment.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult your primary oncology team for personalized treatment decisions.

References

• National Cancer Institute (NCI) - Non-Hodgkin Lymphoma Treatment Overview


• NIH Genetic and Rare Diseases Information Center (GARD)


• Lymphoma Research Foundation (LRF)


• Orphanet: Portal for rare diseases and orphan drugs